Loqtorzi market forecast points to faster growth in NPC care

The Business Research Company says the Loqtorzi market is set for steady expansion through 2035, driven by rising nasopharyngeal carcinoma cases, broader immunotherapy use and global drug approvals. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Loqtorzi is tied to treatment for nasopharyngeal carcinoma, a cancer with rising diagnosis rates and limited treatment options in many markets. - Growing use of PD-1 inhibitors in rare cancers could expand access to immunotherapy for patients with recurrent or metastatic NPC. - The market outlook matters for oncology drug makers, hospitals and research groups tracking biologic therapies.

What happened: - The Business Research Company published its Loqtorzi Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Loqtorzi market is expected to keep growing through the forecast period. - The report links that growth to advances in immunotherapy and oncology research. - The report also highlights rising diagnosis rates of nasopharyngeal carcinoma worldwide.

The details: - Loqtorzi, also known as toripalimab-tpzi, is a biologic drug that blocks the PD-1 receptor on T-cells. - The therapy boosts the immune system’s ability to fight nasopharyngeal carcinoma, especially in metastatic or recurrent cases. - Loqtorzi is used with chemotherapy or as a standalone treatment when disease progresses. - Historical growth came from rising NPC diagnosis rates in endemic areas, PD-1 blockade trial results, increased oncology funding and more specialized cancer treatment centers. - The report says future growth should come from broader global approvals for immunotherapy drugs, more spending on rare-cancer treatments, better access to oncology biologics and more combination-immunotherapy use. - Forecast-period trends include broader adoption of PD-1 inhibitors for rare cancers, greater focus on NPC therapies, expansion of immuno-oncology pipelines, heavier use of immune checkpoint blockade and more global clinical trial activity. - In October 2024, Cancer Research UK projected a 3% increase in head and neck cancer cases in the UK when comparing 2023–2025 with 2038–2040. - The report identifies North America as the largest Loqtorzi market in 2025. - The report says Asia-Pacific will be the fastest-growing region over the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - Free sample report - Full market report

Between the lines: - The report is betting that rare-cancer immunotherapy will gain share as clinical evidence, approvals and access improve. - The regional split suggests mature markets will anchor current sales while Asia-Pacific drives incremental growth. - The focus on forecasting tools and TAM analysis signals demand from investors and strategists looking for category sizing, not just product updates.

What's next: - The report expects clinical trial activity and combination-immunotherapy development to remain key market catalysts. - Wider access to oncology biologics and continued drug approvals could shape adoption through 2035. - Regional investment in cancer care will likely remain a major variable in the pace of market growth.

The bottom line: - Loqtorzi’s market outlook is being pushed by rising NPC burden and broader immunotherapy adoption, with North America leading now and Asia-Pacific positioned to grow fastest.